Oral Anavex 2-73 Eases Dementia, Disease Symptoms in Phase 2 Trial

Oral Anavex 2-73 Eases Dementia, Disease Symptoms in Phase 2 Trial

298068

Oral Anavex 2-73 Eases Dementia, Disease Symptoms in Phase 2 Trial

Anavex Life Sciences’ investigational oral therapy Anavex 2-73 (blarcamesine) leads to clinically meaningful cognitive improvements while reducing motor and non-motor symptoms in people with Parkinson’s disease dementia (PDD), according to data from a Phase 2 trial. These benefits also significantly associated with increases in the levels of sigma-1 receptor (SIGMAR1), Anavex 2-73’s target, confirming the therapy’s biological effects and SIGMAR1 as a reliable response biomarker. The findings, indicating that the trial met its main and secondary efficacy…

You must be logged in to read/download the full post.